Creo Medical Group (LON:CREO) Stock Price Down 4.2% – Time to Sell?

Creo Medical Group PLC (LON:CREO) shares were down 4.2% during mid-day trading on Wednesday . The company traded as low as GBX 15.50 and last traded at GBX 15.80. Approximately 1,069,990 shares changed hands during mid-day trading, a decline of 1% from the average daily volume of 1,079,152 shares. The stock had previously closed at GBX 16.50.

Creo Medical Group Stock Performance

The company has a debt-to-equity ratio of 29.96, a quick ratio of 2.19 and a current ratio of 3.24. The firm’s 50-day moving average price is GBX 13 and its two-hundred day moving average price is GBX 12.10. The stock has a market cap of £65.17 million, a price-to-earnings ratio of -15.80 and a beta of 0.86.

Insider Activity

In other news, insider Craig Jonathan Gulliford purchased 8,036 shares of the company’s stock in a transaction dated Tuesday, January 13th. The stock was acquired at an average price of GBX 11 per share, with a total value of £883.96. Also, insider Richard John Rees purchased 8,036 shares of Creo Medical Group stock in a transaction dated Tuesday, January 13th. The shares were purchased at an average cost of GBX 11 per share, for a total transaction of £883.96. Insiders own 4.11% of the company’s stock.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.